NCT05072977

Brief Summary

surgical correction of ametropia. A number of improvements have been introduced to overcome the side effects and complications such as corneal haze, epithelial irregularities induced by wound healing, pain and delayed visual acuity recovery associated with PRK surgery. During traditional PRK, the corneal epithelium is mechanically debrided before stromal ablation is performed. Alcohol PRK is frequently used as an alternative to mechanical epithelial debridement and is considered simpler and faster. Transepithelial PRK (TransPRK) is a new method in which the corneal epithelium is photoablated by the laser in one step using a specific ablation profile. This study attempts to establish a means of quantitatively and objectively measuring corneal haze, using patented software based on optical coherence tomography (OCT) of the cornea. This will confirm or refute the hypothesis of a lower occurrence of corneal haze after TransPRK (experimental group) versus PRK with alcohol (control group). Each patient will have one eye randomised to one of the two groups being compared.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
71

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 11, 2021

Completed
4 months until next milestone

Study Start

First participant enrolled

February 9, 2022

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2023

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 10, 2024

Completed
Last Updated

December 8, 2025

Status Verified

December 1, 2025

Enrollment Period

1.3 years

First QC Date

September 29, 2021

Last Update Submit

December 2, 2025

Conditions

Keywords

MyopiaAstigmatismCorneal hazeTrans Photorefractive KeratectomyAlcohol Photorefractive Keratectomy

Outcome Measures

Primary Outcomes (1)

  • Corneal haze assessed with the the software analysing the corneal OCT images

    Corneal haze assessed by the intensity of the luminosity of the whole cornea (expressed as a percentage) evaluated by the software analysing the corneal OCT images.

    1 month after refractive surgery

Study Arms (2)

TransPRK

EXPERIMENTAL
Procedure: TransPRK

Alcohol PRK

ACTIVE COMPARATOR
Procedure: Alcohol PRK

Interventions

TransPRKPROCEDURE

A Merocel sponge is soaked in a saline solution to expand before being gently applied to the corneal surface in three gestures similar to painting. This standardised procedure avoids inhomogeneous wetting of the cornea, which would result in uneven ablation. The laser ablation is then performed.

TransPRK
Alcohol PRKPROCEDURE

A ring is placed in the centre of the cornea and filled with 20% alcohol. After 20 seconds of exposure, the alcohol is absorbed with a small sponge and the corneal epithelium is debrided with a polyvinyl alcohol expanding sponge (Merocel, Medtronic). The entire cornea is rinsed with balanced salt solution and the epithelium is peeled away from the corneal stroma. The corneal bed is then dried with a small sponge and laser ablation is performed.

Alcohol PRK

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Planned Photorefractive Keratectomy in both eyes
  • Simple myopia or myopic astigmatism, refractive spherical equivalent between -0.50 and -9.0 diopters in both eyes with regular corneal topography

You may not qualify if:

  • Only one eye operated on
  • At least one contraindication to refractive surgery, namely : keratoconus, minimum corneal thickness \< 400 µm, severe dry syndrome, progressive corneal infection
  • Personal history of corneal surgery
  • Personal history of ocular pathology other than simple myopia or myopic astigmatism
  • Pregnant or breastfeeding woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Fondation A. de Rothschuld

Paris, 75019, France

Location

MeSH Terms

Conditions

MyopiaAstigmatismCorneal Opacity

Interventions

Ethanol

Condition Hierarchy (Ancestors)

Refractive ErrorsEye DiseasesCorneal Diseases

Intervention Hierarchy (Ancestors)

AlcoholsOrganic Chemicals

Study Officials

  • Alain SAAD, MD

    Hôpital Fondation A. de Rothschild

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2021

First Posted

October 11, 2021

Study Start

February 9, 2022

Primary Completion

June 5, 2023

Study Completion

July 10, 2024

Last Updated

December 8, 2025

Record last verified: 2025-12

Locations